Evidence Hub

Moxifloxacin plus Cordyceps polysaccharide ameliorate intestinal barrier damage due to abdominal infection via anti-inflammation and immune regulation under simulated microgravity

Nie HY, Ge J, Liu KG, Yue Y, Li H, Lin HG, Zhang T, Yan HF et al.

Life sciences in space research, 2025

Abstract

BACKGROUND: Currently, there is limited research on the impact of abdominal infection on intestinal damage under microgravity conditions. Cordyceps polysaccharide (CPS), the main active ingredient of Cordyceps, has demonstrated various pharmacological effects, including anti-inflammatory, antioxidant, and immunomodulatory properties. Moxifloxacin (MXF) is a fourth-generation quinolone antibiotic that is believed to have a dual regulatory effect on immune system activation and suppression. Our objective was to investigate the effects of MXF plus CPS on the intestinal barrier damage due to abdominal infection under microgravity.

METHODS: The hindlimb unloading model in rats was employed to simulate microgravity. The rat model of abdominal infection was established by cecal ligation and puncture (CLP). MXF, CPS and the combination of the two drugs were used to treat CLP-rats in simulated microgravity. We assessed histopathological changes of ileum by hematoxylin and eosin staining. The intestinal ultrastructure was observed under transmission electron microscopy. Additionally, the expression of intestinal barrier proteins RegIII α/γ and MUC2 was detected by Western blot analysis, while the localization of these proteins within the ileum was examined using immunohistochemistry. Cytometric bead array (CBA) was employed to detect cytokine including IL-6, TNF-α, IL-1β, IL-1α, CXCL-1, MCP-1, IL-17A, IL-18, and IL-33. Flow cytometry analysis was conducted to determine the percentages…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free